AlphaStreet Newsdesk powered by AlphaStreet Intelligence
Annovis Bio, Inc. reported a widening quarterly loss because the medical stage neurodegenerative drug developer continued to burn by money whereas advancing its therapeutic pipeline. The corporate posted a lack of $0.63 per share for Q1 2026, representing a 96.9% improve from the $0.32 loss recorded in the identical interval final 12 months.
The corporate, which focuses on creating remedies for neurodegeneration, reported a web lack of $17.6M for the quarter. Annovis operated 28.5M shares of frequent inventory excellent at quarter finish because it funds its ongoing medical trials concentrating on situations resembling Alzheimer’s illness and Parkinson’s illness.
Regardless of the deepening losses, Wall Road analysts keep a bullish stance on the Philadelphia-based biotech. Present analyst consensus reveals 7 purchase scores and 1 maintain ranking, with no promote suggestions. The optimistic sentiment seemingly displays optimism in regards to the firm’s drug platform know-how and development of its medical applications, although buyers face the everyday dangers related to early-stage biotechnology firms which have but to generate product income.
The widening loss comes as Annovis continues to put money into analysis and growth of its lead candidates, a typical trajectory for medical stage pharmaceutical firms that prioritize advancing their pipeline over near-term profitability.
This content material is for informational functions solely and shouldn’t be thought of funding recommendation. AlphaStreet Intelligence analyzes monetary knowledge utilizing AI to ship quick and correct market data. Human editors confirm content material.
